Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 273 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide... February 9, 2022 Breast Cancer Surgery Choice May Affect Young Survivors’ Quality of Life September 30, 2021 Bean there done that: Can swapping to pulses be the new... February 11, 2022 Mammograms Can Detect COVID-19 Vaccination Swelling, Causing Cancer Scares March 4, 2021 Load more HOT NEWS How to Find Reliable and Affordable Transportation During Cancer Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... Lazertinib Demonstrates Significant Efficacy Improvement Compared with Gefitinib in the First-Line...
